Overview of cbdMD

cbdMD, Inc. (NYSE American: YCBD), based in Charlotte, North Carolina, is a prominent player in the hemp-derived cannabidiol (CBD) market. The company is dedicated to delivering premium CBD products and has recently made headlines for its progress in securing regulatory approval for its proprietary CBD ingredient.

Advancement in Regulatory Approval

On April 7, 2025, cbdMD announced that its Novel Food dossier (RP793) is in the final phase of assessment by the UK Food Standards Agency (FSA). This advancement highlights the company’s ongoing commitment to safety, quality, and excellence in the rapidly evolving CBD landscape.

The initiation of this process started back in March 2021, when cbdMD submitted a thorough dossier detailing crucial aspects of its proprietary ingredient, including:

• Ingredient identity and quality
• Stability and sourcing of hemp
• Extraction controls and testing requirements
• Labeling and usage instructions
• Extensive safety data

In February 2022, cbdMD emerged as the first U.S. brand to receive validation of its dossier, which marked the beginning of an intensive collaborative effort with the FSA to ensure a smooth review process.

The FSA’s Critical Safety Assessment

On February 28, 2025, the FSA shared its safety assessment regarding cbdMD’s patent-pending CBD isolate (RP793), a high-purity CBD ingredient designed for use in food supplements. This assessment is publicly accessible on the FSA website.

Key Findings from the Scientific Evaluation:

• Purity & Compliance: The CBD isolate is free from harmful contaminants and controlled cannabinoids like THC, confirming adherence to UK food safety regulations.
• Safe Consumption Levels: The FSA supports the data provided by cbdMD on safe intake levels for adults.
• Toxicological Safety: Comprehensive studies affirm the ingredient’s safety when consumed in accordance with guidelines.
• Regulatory Approval Pathway: Products that incorporate cbdMD’s CBD isolate align well with the UK’s stringent novel food criteria, ensuring compliance in the regulated market.

Consumer and Industry Compliance

The FSA emphasizes the importance of purchasing only CBD products that conform to novel food regulations and are listed on their public register. Companies marketing CBD food supplements are obligated to secure regulatory approval to maintain their market presence.

cbdMD is proud to be among the few companies authorized to sell CBD products in the UK and will soon be one of the select brands with an approved Novel Food ingredient. This achievement not only assures consumers of access to safe and compliant products but also strengthens cbdMD’s position as a trustworthy option for wellness solutions.

The Impact of Regulatory Approval

This milestone in cbdMD’s journey underscores its leadership in the CBD sector and is expected to drive greater consumer awareness and sales. With increasing numbers of individuals seeking compliant and rigorously regulated products, cbdMD stands poised to meet these demands effectively.